We are a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer.


 

RECENT HIGHLIGHTS

First oral GLP1r agonist, TTP054, shows robust effects in Type II DM patients not well controlled on metformin.
More Information


HPP404 has completed a 30-day trial in healthy obese subjects where the drug was well tolerated with no CNS related side effects. Despite lack of dietary restrictions a meaningful weight reduction was seen.
More Information

 

Home   |   About Us   |   Therapeutic Areas   |   Discovery Platform   |   Strategic Alliances   |   Press Releases    |   Careers    |   Contact Us    |   Login
© Copyright 2011,Transtech Pharma, Inc., all rights reserved. ® Marks owned by TransTech Pharma, Inc.h Pharma, Inc.
Web Design and Development by BEM Interactive